ArticleJournal of clinical biochemistry and nutrition2025
Adiponectin inhibits chemokine-induced cell migration via direct interaction with platelet factor 4.
Article in Journal of clinical biochemistry and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite adiponectin's recognized anti-inflammatory properties, its impact on cardiovascular homeostasis involves poorly defined mechanisms. We investigated the effect of adiponectin on chemokine-induced cell migration and their potential intermolecular interactions. Our findings revealed that cell migration induced by recombinant PF4, MCP-1, or RANTES in HL-60 cells was significantly inhibited by pre-treating cells with adiponectin. Surface plasmon resonance analysis and molecular docking analysis indicated that only PF4 binds to adiponectin with a higher affinity of adiponectin to the PF4 binding site respectively. These results suggest that adiponectin's atheroprotective functions may be mediated by its ability to reduce PF4-induced monocyte migration through direct interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.